Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)

Fig. 3

Odds ratio of steatosis improvement by subgroups. Response (≥30% relative reduction or ≥5% absolute decline by MRI-PDFF from baseline to end of treatment) by age (≥ or <50), sex, body mass index (≥ or < 30 kg/m2), type 2 diabetes, sarcopenia (skeletal muscle mass index % <2 standard deviations below gender-specific mean for the Korean population: men, 29.0; women, 22.9), HOMA-IR (≥3.7, study median), baseline MRI-PDFF (≥14.3%, study median), and baseline MRE (≥2.1, study median)

Back to article page